Plus   Neg

Medtronic Recalls Specific Lots Of Diabetes Infusion Sets


Medtronic plc (MDT) announced a voluntary recall of specific lots of infusion sets used with all models of its insulin pumps related to a certain discontinued component in these infusion sets.

The company noted that a component, the vent membrane, may be susceptible to being blocked by fluid during the process of priming/fill-tubing, which can lead to potential over-delivery of insulin shortly after an infusion set change, which may cause hypoglycemia and in extreme cases, death.

Medtronic has received reports of hypoglycemia requiring medical intervention potentially related to this issue. Medtronic said will continue working directly with government and regulatory authorities on this global voluntary recall.

Francine Kaufman, chief medical officer of the Diabetes Group at Medtronic, said, "Our Medtronic Diabetes team will work as quickly as possible to complete all exchanges to the new and enhanced set and fully support our customers throughout this process."

Medtronic expects this recall of infusion sets not to impact Diabetes Group revenue growth in the second quarter or the full fiscal year.

The company has provided the website https://checklots.medtronicdiabetes.com to determine which REF and LOT numbers of the infusion sets are part of this recall.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT